Agenus (AGEN) Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
6/26/2014 10:46:41 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2). HerpV contains a defined mixture of peptides representing HSV-2 antigens plus Agenus’ QS-21 Stimulon® adjuvant.
Help employers find you! Check out all the jobs and post your resume.
comments powered by